Article
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.
The British journal of dermatology - 1 Nov 2018
Costanzo A, Bianchi L, Flori M L, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G
Abstract excerpt
BACKGROUND: Understanding genetic variations is important in predicting treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for psoriasis treatment. There are limited data on the efficacy of secukinumab in relation to genetic markers. OBJECTIVES: To evaluate the efficacy and safety of secukinumab 300 mg in HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.